KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$0.16.

  • Biomarin Pharmaceutical's EPS (Basic) fell 12857.14% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.72, marking a year-over-year increase of 6000.0%. This contributed to the annual value of $2.25 for FY2024, which is 15239.41% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EPS (Basic) is -$0.16, which was down 12857.14% from $1.25 recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EPS (Basic) peaked at $1.25 during Q2 2025, and registered a low of -$0.32 during Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median EPS (Basic) value was $0.21 (recorded in 2023), while the average stood at $0.3.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 45555.56% in 2021, then surged by 120000.0% in 2023.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's EPS (Basic) stood at -$0.32 in 2021, then surged by 96.88% to -$0.01 in 2022, then surged by 1200.0% to $0.11 in 2023, then soared by 497.73% to $0.66 in 2024, then tumbled by 124.33% to -$0.16 in 2025.
  • Its EPS (Basic) was -$0.16 in Q3 2025, compared to $1.25 in Q2 2025 and $0.97 in Q1 2025.